sometimes you can,, break old, bad habits
Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test
https://youtu.be/XVrwE1FYAiQ
We Do Wholesale Better!
Increased Opportunity
We are a 50-state licensed distributor of generic, injectable, specialty, OTC and supplement products. We help your pharmacy do more with less. Our buying power offers you more competitive pricing on products spanning all major disease states.
https://www.wellgistics.com/
Bruce, i hope you are right. i am sure the last eight weeks has not been good for your financial health. You put in much work here in these threads. So thanks for that. The important thing here is are the covid antibody test kits effective that Pred is involved in. if so a game changer.
Many companies are trying to get test kits out in the market place that are much bigger and have much more man power than Pred. The race is on. Hopefully Pred has the know how to get to the finish line first, hell second would even be great. Preds past performance lines are not too great but that is what makes a horse race. Long shots do occasionally come in. Let us hope this is one of those long shots.
Please read the above posted article from the daily beast regarding Abbott labs.
I didn't write this but sharing because I believe it is accurate and important
Per my previous posts, things are looking up here and you haven’t seen anything yet!
I’m hearing a lot of things re big orders and governments (national and international) looking to get heavily involved. Testing is the key and it’s not going to be a one off. When we all get back to work (not soon but it will happen) employers will have to test test test. I’ve heard that management and boards have been advised by attorneys that if they don’t have testing protocols in place, they are open to lawsuits for neglect in relation to employee welfare. Testing will be a main stay for 12-24 months
2nd there are not enough tests, the abbot test is a farce as most can’t get access to it and it only tests for the virus at that moment. If you get it 1 minute later or had the virus 3 weeks earlier, it’s useless. There are no viable antibody test out there in the volume required apart from Assurance AB from predictive Labs. Even predictive will only be able to fill 1-2% of the demand. The WHO is saying we will need 7B tests in the next 12 months. It’s an impossible number.
3 there will be lots of tests at lots of price points but they will vary in quality and pricing. The AssuranceAB test is aimed at point of care for now and you want the best test for those people. You need to test for IGM and IGG as the antibodies appear at different times and just testing for one is a death sentence as you could be infected and not know it. That’s why single antibody tests don’t work and are cheap. Who wants 60% accuracy when it’s your family’s health!
4 China is cracking down on the sub standard product coming out of there. As of April 1 they only allow approved products leave their ports. Thai eliminates 85% of all the crap that’s out there, making AssuranceAB even more desirable.
5 I expect them to get EUA approval in the coming weeks making them the first company with a proper EUA. Cellexs EUA granted yesterday was pointless! It can only be used in a lab
6 we have all forgotten about the stem cells! Don’t be surprised if they start releasing stemcell news as well as the AssuranceAB news!
7 pred may just be the perfect company in this covid storm with viral testing pcr )they can do this as they are a clia lab) rapid testing with AssuranceAB and potential treatments with stem cells!
8 all of the above leads to massive price gains in the stock.
Predictive Technology Group Announces Initial Order of One Million Units of the Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test from Distribution Partner, Wellgistics, LLC.
Email Print Friendly Share
April 08, 2020 08:00 ET | Source: Predictive Technology Group Inc
SALT LAKE CITY, April 08, 2020 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), today shared that its distribution partner, Wellgistics, has submitted an initial order for immediate delivery of one (1) million units of the Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test (Assurance AB) intended for use by laboratories and healthcare workers at the point-of-care in the U.S.
“We have been working diligently with Wellgistics to get this first order put in motion, even prior to making our partnership announcement on April 3,” said Bradley Robinson, CEO of Predictive Technology Group. “This country is in high need of the Assurance AB testing for point of care use and we have brought all resources to bear to bring this product to the United States. Wellgistics has provided us with state-by-state demand guidance, to ensure that regions with the most urgent need have first access to the test. Our main priorities will be to focus on servicing those areas,” Robinson continued.
“When our partnership with Predictive was announced last week, our team was very aware of the coming tsunami wave of interest for this test,” said Brian Norton, CEO of Wellgistics. “This demand grows each day as more attention hits the media and is recognized as a viable solution toward identifying immunity and allowing people to go back to work. Presently, the Wellgistics team is hyper focused on closing the final gaps of the complex web of international logistics. We feel great about where we are, and we will provide new updates as quickly as they are available.”
Predictive announced website updates relating to Assurance AB including:
Instructions For Use, Quick Reference Guide and Fact Sheet for laboratories and healthcare workers at the point-of-care. The website also includes an instructional video on administering the Assurance AB test.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests and companion therapeutics in order to support a patient from diagnosis through treatment.
Dedicated to identifying the barriers that impact lifelong health through our genetic library, genomic mapping and individualized diagnostics, Predictive’s tests and products empower clinicians to provide their patients with the highest level of care. For more information, visit www.predtechgroup.com
About Predictive Laboratories, Inc.
Predictive Laboratories’ molecular and genetic diagnostics focus on hard-to-diagnose and hard-to-detect diseases. Leveraging its vast genetic library, Predictive offers earlier detection of a variety of diseases through genetic assessments to guide personalized precision medicine.
Equipped with a state-of-the-art CAP and CLIA accredited laboratory, Predictive operations perform next-generation sequencing experiments, including whole exome sequencing, gene and genetic marker panels, and low-pass whole genome analysis of embryos for aneuploidies. Predictive arms physicians with the most robust diagnostic tools to provide personalized precision treatment for their patients. For more information, visit www.predictivelabs.com
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Predictive Laboratories
Info@predictivelabs.com
855-497-3636
Investor Contact
Jeremy Feffer
LifeSci Advisors
jeremy@lifesciadvisors.com
212-915-2568
[h=1]Predictive Submits Emergency Use Authorization Application for Treatment of Acute Respiratory Distress Syndrome Secondary to COVID -19 with Umbilical Cord Mesenchymal Stem Cells[/h][h=2][/h][FONT="]https://www.globenewswire.com/news-...h-Umbilical-Cord-Mesenchymal-Stem-Cells.html#[FONT="][/FONT][FONT="][/FONT][FONT="][/FONT][FONT="][/FONT][FONT="][/FONT]Email [FONT="][/FONT]Print Friendly [FONT="][/FONT]Share
April 13, 2020 08:00 ET | Source: Predictive Technology Group Inc
SALT LAKE CITY, April 13, 2020 (GLOBE NEWSWIRE) -- Predictive Biotech, a wholly owned subsidiary of Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), announced that on April 9[SUP]th[/SUP] it submitted an Emergency Use Authorization (EUA) application with the U.S. Food and Drug Administration (FDA) for the immediate use of mesenchymal stem cells (MSCs) derived from umbilical cord tissue for the treatment of Acute Respiratory Distress Syndrome (ARDS), secondary to SARS-CoV-2, coronavirus disease 2019 (COVID-19).
The pandemic caused by COVID-19 has shown to develop into severe ARDS in 30% of hospitalized patients with a 22%-62% mortality rate (Murthy et al., 2020) for those requiring hospitalization in an intensive care unit. Currently, there is no confirmed treatment that can demonstrate safety or efficacy for the treatment of COVID-19.
“Coronavirus can be deadly, in large part because the virus can cause ‘cytokine storms’ in which the patient’s own immune system triggers a runaway response causing more damage to the patient, than to the virus it's trying to eliminate,” said John Sorrentino, Chairman of Predictive Technology Group. “Respiratory distress kills hundreds of thousands of people each year worldwide. There is clinical data from early clinical trials that seem to indicate that the avoidance of the cytokine storm utilizing MSCs may be a critical component for the treatment of COVID-19 infected patients.”
A recent review article published in Pain Physician, concluded that, “The limited but emerging evidence regarding UC MSC [umbilical cord mesenchymal stem cells] in managing COVID-19 suggests that it might be considered for compassionate use in critically ill patients to reduce morbidity and mortality in the United States.”
The proposed IND clinical trial will utilize Predictive’s proprietary core technology of naturally occurring MSCs derived from umbilical cord tissue (UC-MSCs) to assess the efficacy as an add-on therapy to standard treatment of patients with severe Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19.
Predictive’s UC MSC product, CoreCyte™, [currently regulated by the FDA as a tissue-based product under 21 CFR 1271.3(d)(1) and Section 361 of the Public Health Service Act] has already been used as an allograft in over 50,000 patients. Physicians have reported to Predictive that over 1,100 patients have been treated with CoreCyte via intravenous administration. No serious adverse events have been reported with CoreCyte regardless of the route of administration. If Predictive’s EUA request is approved, CoreCyte would be available immediately to critically ill patients with ARDS due to COVID-19 infections.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests and companion therapeutics in order to support a patient from diagnosis through treatment.
Dedicated to identifying the barriers that impact lifelong health through our genetic library, genomic mapping and individualized diagnostics, Predictive’s tests and products empower clinicians to provide their patients with the highest level of care. For more information, visit [url]www.predtechgroup.com[/URL]
About Predictive Biotech, Inc.
Predictive Biotech is a leader in regenerative medicine, its products are derived from tissue sources rich in properties that support the body’s natural ability to heal itself. All products are safely, ethically and minimally processed to deliver allografts that preserve the naturally occurring characteristics and factors of the donor tissue. Predictive’s signature products are uniquely born from the Wharton’s jelly layer of the umbilical cord and amniotic fluid and tissue.
With over 100,000 units delivered, product safety and consistency has been realized by thousands of practices throughout the United States. A national network of clinics, health systems, researchers and physicians leverage Predictive’s four proprietary products: AmnioCyte™, AmnioCyte Plus™, PolyCyte™, and CoreCyte™.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks The Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect The Company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect The Company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by The Company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Predictive Biotech
Info@predictivebiotech.com
888-407-9761
Investor Contact
Jeremy Feffer
LifeSci Advisors
jeremy@lifesciadvisors.com
212-915-2568
[/FONT]
ByAlex Carlson
Posted on April 13, 2020
SH
TWEET
SHARE
COMMENTS
The biggest problem facing the world right now is the coronavirus crisis. While it is tragic what is happening, there’s a huge opportunity for investors that can invest in the companies that will solve this crisis. There are two segments for investors to focus on – those companies working on a vaccine and ones companies working on testing for coronavirus. One stock which we’ve identified that has enormous potential in the testing phase is Predictive Technology Group (OTCMKTS
RED).https://insiderfinancial.com/predictive-technology-group-otcmktspred-covid-19-testing/179804/
[h=1]Predictive Biotech and an EUA for CoreCyte?[/h]By Chris Centeno, MD / April 15, 2020
https://regenexx.com/blog/predictive-biotech-and-an-eua-for-corecyte/
https://regenexx.com/blog/predictive-biotech-and-an-eua-for-corecyte/
